The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom by Schwarze, K, Buchanan, J, Fermont, JM, Dreau, H, Tilley, MW, Taylor, JM, Antoniou, P, Knight, SJL, Camps, C, Pentony, MM, Kvikstad, EM, Harris, S, Popitsch, N, Pagnamenta, AT, Schuh, A, Taylor, JC, Wordsworth, S

Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer by Purshouse, K, Schuh, A, Fairfax, B, Knight, S, Antoniou, P, Dreau, H, Popitsch, N, Gatter, K, Roberts, I, Browning, L, Traill, Z, Kerr, D, Verrill, C, Tuthill, M, Taylor, J, Protheroe, A

Clinical‐grade validation of whole genome sequencing reveals robust detection of low‐frequency variants and copy number alterations in CLL by Klintman, J, Barmpouti, K, Knight, S, Robbe, P, Dreau, H, Clifford, R, Ridout, K, Burns, A, Timbs, A, Bruce, D, Antoniou, P, Sosinsky, A, Becq, J, Bentley, D, Hillmen, P, Taylor, J, Caulfield, M, Schuh, A

Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing by Schuh, A, Dreau, H, Knight, SJL, Ridout, K, Mizani, T, Vavoulis, D, Colling, R, Antoniou, P, Kvikstad, EM, Pentony, MM, Hamblin, A, Protheroe, A, Parton, M, Shah, KA, Zsolt, O, Athanasou, N, Hassan, B, Flanagan, AM, Ahmed, A, Winter, S, Harris, A, Tomlinson, I, Popitsch, N, Church, DN, Taylor, JC

Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project. by Robbe, P, Popitsch, N, Knight, SJL, Antoniou, P, Becq, J, He, M, Kanapin, A, Samsonova, A, Vavoulis, DV, Ross, MT, Kingsbury, Z, Cabes, M, Ramos, SDC, Page, S, Dreau, H, Ridout, K, Jones, LJ, Tuff-Lacey, A, Henderson, S, Mason, J, Buffa, FM, Verrill, CL, Maldonado-Perez, D, Roxanis, I, Collantes, E, Browning, L, Dhar, S, Damato, SP, Davies, S, Caulfield, M, Bentley, DR, Taylor, JC, Turnbull, C, Schuh, A